Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma  

作　　者：Ping Li Ningxin Dong Yu Zeng Jie Liu Xiaochen Tang Junbang Wang Wenjun Zhang Shiguang Ye Lili Zhou Alex Hongsheng Chang Aibin Liang 

机构地区：[1]Department of Hematology,Tongji Hospital of Tongji University School of Medicine,Shanghai 200065,China [2]Department of Imaging,Tongji Hospital of Tongji University School of Medicine,Shanghai 200065,China [3]Clinical Translational Research Center,Shanghai Pulmonary Hospital of Tongji University School of Medicine,Shanghai 200433,China

出　　处：《Frontiers of Medicine》2020年第6期811-815,共5页医学前沿（英文版）

基　　金：This study was supported by grants from the Shanghai Municipal Hospital New Frontier Technology Joint Research Project(No.SHDC12015108);the National Natural Science Foundation of China(Nos.81830004,31301118,and 81272325);the Fundamental Research Funds for the Central Universities(No.22120170004).

摘　　要：Mantle cell lymphoma(MCL)is a distinct histological type of B-cell lymphoma with a poor prognosis.Several agents,such as proteasome inhibitors,immunomodulatory drugs,and inhibitors of B cell lymphoma-2 and Bruton’s tyrosine kinase have shown efficacy for relapsed or refractory(r/r)MCL but often have short-term responses.Chimeric antigen receptor(CAR)T-cell therapy has emerged as a novel treatment modality for r/r non-Hodgkin’s lymphoma.However,long-term safety and tolerability associated with CAR T-cell therapy are not defined well,especially in MCL.In this report,we described a 70-year-old patient with r/r MCL with 48-month duration of follow-up who achieved long-term remission after CAR T-cell therapy.CAR T-cell-related toxicities were also mild and tolerated well even in this elderly patient.This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL,who are generally elderly and have comorbid conditions.

关 键 词：anti-CD19 chimeric antigen receptor T cells mantle cell lymphoma relapsed or refractory long-term follow-up 

分 类 号：R733.4[医药卫生—肿瘤]